Back to top
more

Mustang Bio (MBIO)

(Delayed Data from NSDQ)

$0.32 USD

0.32
269,294

-0.03 (-9.79%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.32 0.00 (1.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MBIO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Mustang Bio, Inc. [MBIO]

Reports for Purchase

Showing records 21 - 40 ( 51 total )

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

02/18/2022

Company Report

Pages: 8

MB-105 Shows Early Activity in PSCA+ Metastatic Prostate Cancer

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

01/25/2022

Daily Note

Pages: 5

MB-207 on Administrative Hold Ahead of Phase 2 Initiation; Thesis Unchanged

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

12/17/2021

Company Report

Pages: 6

KOL Event Spotlights MB-106 Differentiated Profile; Company-Led Trial Expected in 1Q22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

12/13/2021

Daily Note

Pages: 6

MB-106 Continues Its Impressive Push Forward; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

11/12/2021

Company Report

Pages: 5

3Q21 Results; Continued Flurry of Activity; ASH Next Up With Important MB-106 Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for MBIO

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

08/17/2021

Company Report

Pages: 6

2Q21 Results; Clinical Updates for Pivotal XSCID Program Expected Shortly;CAR-T Platform Continues to Strengthen

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

08/03/2021

Daily Note

Pages: 3

Regulatory Update Bodes Well for MB-107 Program

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

06/14/2021

Company Report

Pages: 7

Cornerstone MB-106 Data at EHA Set Up Broader Studies; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

05/17/2021

Company Report

Pages: 6

1Q21 Results; XSCID Going Pivotal and MB-106 at EHA Shortly; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

03/25/2021

Company Report

Pages: 8

2020 Results; Stage Set For Pivotal Program in XSCID and Updates Across CAR-T Platform

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

02/03/2021

Company Report

Pages: 7

Encouraging Updates Bode Well for Pivotal Phase 2 Trial in XSCID

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

12/10/2020

Company Report

Pages: 8

KOL Call Highlights Differentiated Safety Profile and Compelling Clinical Activity Underscoring MB-106

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

12/07/2020

Company Report

Pages: 8

CD20 Has a New Enemy in MB-106; Impressive ASH Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

11/10/2020

Company Report

Pages: 6

3Q20 Results; Further Visibility on CAR-T Differentiation Next up at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

10/26/2020

Daily Note

Pages: 4

MB-105 Triggers Promising Clinical Response in PSCA-mCRPC; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

10/01/2020

Daily Note

Pages: 4

MB-102 Hits the Clinic; Could Make a Big Splash; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

08/31/2020

Daily Note

Pages: 3

Racking up the Regulatory Designations; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

08/17/2020

Daily Note

Pages: 3

MB-107 Could Generate a Big Check

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

08/11/2020

Company Report

Pages: 6

2Q20 Results; Driving Quickly Toward Next Data Updates

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party